MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Gilead Sciences Inc.

Geschlossen

BrancheGesundheitswesen

112.37 0.34

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

111.88

Max

114.59

Schlüsselkennzahlen

By Trading Economics

Einkommen

530M

1.8B

Verkäufe

29M

7.6B

KGV

Branchendurchschnitt

294.868

63.778

EPS

1.9

Dividendenrendite

2.82

Gewinnspanne

23.557

Angestellte

17,600

EBITDA

-655M

3.1B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+3.07% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.82%

2.39%

Nächstes Ergebnis

24. Apr. 2025

Nächste Dividendenausschüttung

26. Juni 2025

Nächstes Ex-Dividendendatum

13. Juni 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

18B

140B

Vorheriger Eröffnungskurs

112.03

Vorheriger Schlusskurs

112.37

Nachrichtenstimmung

By Acuity

14%

86%

19 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Gilead Sciences Inc. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Feb. 2025, 21:17 UTC

Ergebnisse

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

19. Dez. 2024, 15:25 UTC

Wichtige Markttreiber

Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding

19. Dez. 2024, 13:38 UTC

Wichtige Markttreiber

Assembly Biosciences Gets $30.1 Million Equity Investment, Funding From Gilead

6. Nov. 2024, 22:25 UTC

Ergebnisse

Gilead Sciences Post Higher 3Q Revenue, Raises Fiscal Year Guidance

19. März 2025, 14:50 UTC

Top News

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28. Feb. 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11. Feb. 2025, 22:13 UTC

Market Talk
Ergebnisse

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11. Feb. 2025, 21:06 UTC

Ergebnisse

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences Raises Dividend 2.6%>GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences Sees 2205 Veklury Sales $1.4B>GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences Sees 2025 Sales $28.2B-$28.6B >GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences 4Q >GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences 4Q HCV Products Sales >GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences 4Q Rev Up on HIV, Oncology, Liver Disease; Partially Offset by lower sales of Veklury (Remdesivir) >GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences 4Q Adj EPS $1.90 >GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences 4Q Rev $7.57B >GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences 4Q EPS $1.42 >GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences 4Q EPS $1.42 >GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences 4Q Net $1.78B >GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences 4Q Rev $7.6B >GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences 4Q Adj EPS $1.90 >GILD

10. Jan. 2025, 10:30 UTC

Top News

Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point. -- WSJ

29. Dez. 2024, 08:00 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Buys $20.1 Million of Assembly Biosciences Stock -- Barrons.com

19. Dez. 2024, 13:23 UTC

Wichtige Markttreiber

Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead

7. Nov. 2024, 16:23 UTC

Ergebnisse

Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise -- IBD

Peer-Vergleich

Kursveränderung

Gilead Sciences Inc. Prognose

Kursziel

By TipRanks

3.07% Vorteil

12-Monats-Prognose

Durchschnitt 115.33 USD  3.07%

Hoch 140 USD

Tief 90 USD

Basierend auf 23 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Gilead Sciences Inc. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

23 ratings

17

Buy

6

Halten

0

Sell

Technischer Score

By Trading Central

109.72 / 112.38Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Neutral Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

19 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.